Literature DB >> 17628803

Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies.

Takamasa Wayaku1, Minoru Hasegawa, Kenzo Kaji, Miki Kondo, Yuki Saito, Hidemitsu Orito, Mayuka Horikawa, Takashi Matsushita, Kazuhiro Komura, Ikuko Hayakawa, Yasuhito Hamaguchi, Fumihide Ogawa, Manabu Fujimoto, Kazuhiko Takehara, Shinichi Sato.   

Abstract

To determine the prevalence of antibodies to individual histone components in collagen disease patients with anti-U1RNP antibodies. Serum samples were examined by enzyme-linked immunosorbent assay. Patients with mixed connective tissue disease (MCTD) and systemic sclerosis (SSc) showed similar levels and patterns of antihistone antibody (AHA) reactivities to individual histones: IgG responses to H2B or H3 and IgM responses to H2B were highest. However, both IgG and IgM AHAs against outer portion of chromatin (H1, H2A, or H2B) were generally higher in SLE compared with other diseases. SLE or SSc patients with anti-U1RNP antibodies showed generally higher AHA levels than in those without them. Thus, the pattern of reactivities to each histone component was dependent on the disease, while the intensity was dependent on both the disease and anti-U1RNP antibodies. The antigenic stimulus in SLE may be different from other connective tissue diseases and is more likely to be native chromatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628803     DOI: 10.1007/s00296-007-0398-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Problems in differentiating SLE and mixed connective-tissue disease.

Authors:  M Reichlin
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

3.  Antihistone antibodies in systemic lupus erythematosus.

Authors:  R L Rubin; S Waga
Journal:  J Rheumatol Suppl       Date:  1987-06

4.  Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA).

Authors:  A Gaudreau; B Amor; M F Kahn; A Ryckewaert; J Sany; A P Peltier
Journal:  Ann Rheum Dis       Date:  1978-08       Impact factor: 19.103

Review 5.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

6.  Mixed connective tissue disease: a subsequent evaluation of the original 25 patients.

Authors:  S H Nimelstein; S Brody; D McShane; H R Holman
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

7.  Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis.

Authors:  M Kubo; H Ihn; N Yazawa; S Sato; K Kikuchi; K Tamaki
Journal:  J Invest Dermatol       Date:  1999-05       Impact factor: 8.551

8.  Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; H Ihn; K Kikuchi; K Takehara
Journal:  J Am Acad Dermatol       Date:  1994-10       Impact factor: 11.527

9.  Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.

Authors:  M C Totoritis; E M Tan; E M McNally; R L Rubin
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

10.  Monoclonal antibodies against distinct determinants of histone H5 bind to chromatin.

Authors:  E Mendelson; M Bustin
Journal:  Biochemistry       Date:  1984-07-17       Impact factor: 3.162

View more
  2 in total

1.  Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties.

Authors:  Ewa Wielosz; Maria Majdan; Iwona Zychowska; Radosław Jeleniewicz
Journal:  Rheumatol Int       Date:  2008-03-05       Impact factor: 2.631

2.  Loading of nuclear autoantigens prototypically recognized by systemic lupus erythematosus sera into late apoptotic vesicles requires intact microtubules and myosin light chain kinase activity.

Authors:  M Zirngibl; B G Fürnrohr; C Janko; L E Munoz; R E Voll; C D Gregory; G Schett; M Herrmann
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.